Jarden keeps Buy rating for EBOS Group stock as target reaches AUD 23.81

Published on 10/15/2026 at 18:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

EBOS ran more than 780 pharmacies in fiscal year 2026. EBOS Group stock costs EUR 10.00 on October 15, 2026, up 3.33 percent on the ASX.

Analyst target and market position

Jarden maintained its Buy rating while the consensus target stood at AUD 23.81 on October 14, 2026.
EBOS operated more than 780 pharmacies in fiscal year 2026.
EBOS Group stock costs EUR 10.00 at Lang & Schwarz on October 15, 2026 at 6:35 p.m. CEST, up 3.33 percent on the ASX.
EBOS had a price-to-earnings ratio of 15.43 and market capitalization of AUD 3.4 billion.

EBO, NZEBOE0001S6, Illustration mit AI erstellt.

Jarden maintained a Buy rating for EBOS Group on October 14, 2026, while the consensus target stood at AUD 23.81, according to The Globe and Mail. Against the ASX price of AUD 16.44, that target is 44.83 percent higher. EBOS Group stock was EUR 10.00 at Lang & Schwarz on October 15, 2026 at 6:35 p.m. CEST, while the ASX session had risen 3.33 percent.

EBOS expands its pharmacy network

EBOS operated more than 780 pharmacies across three banners in fiscal year 2026, according to the EBOS Group annual report. The network represented more than 13 percent of Australia's community pharmacies, giving the retail division a visible scale advantage within the group's healthcare portfolio.

Price position and trading activity

The ASX quote was AUD 16.44 on October 15, 2026 at 4:10 p.m. CEST, with a daily gain of 3.33 percent. Trading volume reached 137,725 shares against an average of 111,238, or 23.78 percent higher than the average. The 52-week range was AUD 14.87 to AUD 26.05, placing the price 10.57 percent above its low and 36.89 percent below its high.

EBOS held a market capitalization of AUD 3.4 billion and a price-to-earnings ratio of 15.43 on October 15, 2026. Its trailing dividend yield was 6.00 percent. The consensus target of AUD 23.81 was 44.83 percent above the ASX price, based on the analyst coverage reported by The Globe and Mail.

Comparison with peers

EBO: plus 3.33 percent, P/E 15.43, market capitalization AUD 3.4 billion

CSL (ASX, AUD): plus 1.25 percent, market capitalization AUD 89.7 billion

Sigma Healthcare (ASX, AUD): unchanged, P/E 45.62, market capitalization AUD 32.4 billion

What matters for the valuation

The share price sits well above its 52-week low but below its high, while the analyst target remains above the latest ASX quotation. The contrast gives investors two measurable reference points: a 10.57 percent cushion over the annual low and a 44.83 percent gap to the consensus target.

EBOS Group stock was trading at EUR 10.00 at Lang & Schwarz on October 15, 2026 at 6:35 p.m. CEST; the ASX session had gained 3.33 percent on the day.

The further course of trading is shown by the continuously updated real-time quote of EBOS Group stock.